ATE248604T1 - Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff - Google Patents

Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff

Info

Publication number
ATE248604T1
ATE248604T1 AT96927257T AT96927257T ATE248604T1 AT E248604 T1 ATE248604 T1 AT E248604T1 AT 96927257 T AT96927257 T AT 96927257T AT 96927257 T AT96927257 T AT 96927257T AT E248604 T1 ATE248604 T1 AT E248604T1
Authority
AT
Austria
Prior art keywords
viruses
neoplastic cells
herpetic
avirulent
tumoricidal
Prior art date
Application number
AT96927257T
Other languages
English (en)
Inventor
Ian J Mohr
Yakov Gluzman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE248604T1 publication Critical patent/ATE248604T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96927257T 1995-07-27 1996-07-25 Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff ATE248604T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US160295P 1995-07-27 1995-07-27
PCT/US1996/012281 WO1997004804A1 (en) 1995-07-27 1996-07-25 Avirulent herpetic viruses useful as tumoricidal agents and vaccines

Publications (1)

Publication Number Publication Date
ATE248604T1 true ATE248604T1 (de) 2003-09-15

Family

ID=21696918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927257T ATE248604T1 (de) 1995-07-27 1996-07-25 Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff

Country Status (10)

Country Link
EP (1) EP0841943B1 (de)
AT (1) ATE248604T1 (de)
AU (1) AU725557B2 (de)
CA (1) CA2227860C (de)
DE (1) DE69629819T2 (de)
DK (1) DK0841943T3 (de)
ES (1) ES2205053T3 (de)
IL (1) IL118942A (de)
WO (1) WO1997004804A1 (de)
ZA (1) ZA966287B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
WO2001016331A1 (en) * 1999-08-31 2001-03-08 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
PT1252322E (pt) 2000-01-21 2005-03-31 Biovex Ltd Estirpes de virus de herpes para terapia genica
CA2352439A1 (en) * 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment

Also Published As

Publication number Publication date
WO1997004804A1 (en) 1997-02-13
CA2227860A1 (en) 1997-02-13
DE69629819T2 (de) 2004-05-06
IL118942A (en) 2002-09-12
IL118942A0 (en) 1996-10-31
ZA966287B (en) 1998-03-09
DE69629819D1 (de) 2003-10-09
DK0841943T3 (da) 2003-12-08
ES2205053T3 (es) 2004-05-01
EP0841943B1 (de) 2003-09-03
AU6713996A (en) 1997-02-26
CA2227860C (en) 2011-05-24
AU725557B2 (en) 2000-10-12
EP0841943A1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
Fields et al. Genetic and molecular mechanisms of viral pathogenesis: implications for prevention and treatment
Sabin et al. Behavior of noninfectious SV 40 viral genome in hamster tumor cells: induction of synthesis of infectious virus
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
ATE73348T1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
ES2074950A1 (es) Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
FR16C0026I2 (fr) Souches de virus herpetique pour therapie genique
DE69121452D1 (de) Gen-Sequenzentransfer und -exprimierung bei Zellen des zentralen Nervensystems mit mutierenden Herpes-Simplex-Viren, die Deletionen in Viren-Replikationsgenen enthalten
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
JP2003520044A5 (de)
WO1994021807A3 (en) Defective mutant non-retroviral virus (e.g. hsv) as vaccine
ATE248604T1 (de) Avirulente herpetische viren verwendbar als tumorzerstörendes agens und impfstoff
NZ315357A (en) Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
CA2073288A1 (en) Manipulation of gene copy number in bordetella
Xiao et al. Efficient strategy for synthesizing vector-free and oncolytic Herpes simplex type 1 viruses
Vahlne et al. Herpes simplex virus infection of mouse neuroblastoma cells
EP0326127A3 (de) Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE277634T1 (de) Assembly-defizientes herpesvirus als impfstoff
WO1994000586A3 (fr) Mutants et vaccins du virus de la rhinotracheite infectieuse bovine
WO1996001615A3 (en) Hepatitis a virus deletion mutants and vaccine formulations containing the same
Pilipenko et al. Distinct attenuation phenotypes caused by mutations in the translational starting window of Theiler’s murine encephalomyelitis virus
Koch et al. Mutants of simian virus 40 which differ in cell-transforming activity
EP1032418A4 (de) Kompakte replikons des epstein-barr-virus.
Hradečná X-ray Inactivation of Lambda Phage: II. Reactivation Processes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0841943

Country of ref document: EP

REN Ceased due to non-payment of the annual fee